ALPHA 1-ANTITRYPSIN DEFICIENCY
Clinical trials for ALPHA 1-ANTITRYPSIN DEFICIENCY explained in plain language.
Never miss a new study
Get alerted when new ALPHA 1-ANTITRYPSIN DEFICIENCY trials appear
Sign up with your email to follow new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New shot aims to stop liver damage in rare genetic disease
Disease control CompletedThis Phase 2 study tested a drug called fazirsiran in 40 adults with Alpha-1 antitrypsin deficiency, a genetic condition that can cause liver disease. The drug is designed to lower levels of a harmful protein (Z-AAT) in the blood. Researchers measured safety and how much the prot…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug targets liver damage in rare genetic disease
Disease control CompletedThis study tested a drug called fazirsiran in 16 people with alpha-1 antitrypsin deficiency, a genetic condition that can cause liver damage. The drug aims to reduce harmful protein buildup in the liver. Researchers measured changes in liver protein levels and safety over 24 to 4…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Healthy volunteers help test new Alpha-1 drug safety
Knowledge-focused CompletedThis early-stage study tested the safety and how the body processes a new drug called ARO-AAT in 45 healthy adults. The goal was to see if the drug is safe and to measure its levels in the blood. This research is a first step toward a possible treatment for Alpha-1 Antitrypsin De…
Matched conditions: ALPHA 1-ANTITRYPSIN DEFICIENCY
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC